GlassScriptPhysician profile
Rajeev Rajani
NPI 1316038698
$6,480.95
in general payments reported to CMS, 2019-2025
33 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $835 · 2021: $971 · 2022: $1,087 · 2023: $1,227 · 2024: $636 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,260.20 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $887.53 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $765.67 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $520.75 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $386.42 | 2019-2024 | Xarelto |
| Medtronic, INC. | $313.80 | 2023 | Cobalt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.19 | 2019-2025 | Jardiance |
| Pfizer INC. | $196.79 | 2019-2023 | |
| Smith+Nephew, INC. | $172.60 | 2019-2021 | |
| Amarin Pharma, INC. | $162.02 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $155.53 | 2019-2023 | |
| Astellas Pharma US INC | $135.49 | 2019-2021 | |
| Horizon Therapeutics Plc | $124.98 | 2022 | |
| Lilly USA, LLC | $119.75 | 2021-2025 | Mounjaro, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $118.45 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $114.67 | 2019 | |
| Esperion Therapeutics, INC. | $98.71 | 2021-2024 | Nexletol |
| Boston Scientific Corporation | $95.31 | 2023-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $94.54 | 2019-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $80.15 | 2023-2024 | Cologuard Collection Kit |
| Organogenesis INC. | $46.38 | 2025 | Simplimax |
| Axonics, INC. | $44.57 | 2022-2024 | Axonics |
| Biogen, INC. | $43.62 | 2021 | |
| Sunovion Pharmaceuticals INC. | $34.35 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $32.71 | 2022-2024 | Zoryve |
| Radius Health, INC. | $30.60 | 2023-2024 | Tymlos |
| Abbott Laboratories | $27.63 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $22.88 | 2022 | |
| Eisai INC. | $20.23 | 2021 | |
| Genentech USA, INC. | $19.73 | 2019 | |
| Abbvie INC. | $18.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.56 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Rajani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.